Fig. 8.
Fig. 8. CD28 stimulation enhances IL-8 production by myeloma cells. / Jurkat T cells, RPMI 8226, SK-MM-1, or H929 human myeloma cells were stimulated with PMA, 25 ng/mL for Jurkat, SK-MM-1, and H929, 1 ng/mL for RPMI 8226, 1 μM ionomycin, 1 μg/mL anti-CD28, and/or 1 μg/mL isotype-matched control antibody MOPC195 as indicated. The cells were used at a concentration of 1 × 106/mL. After 18 hours, the supernatants were tested for IL-8 by ELISA, using the matched antibody pair and reagents from Pierce-Endogen as per the manufacturer's instructions. Within each experiment, the stimulations were performed in triplicate. The results shown are the average of 3 independent experiments. Error bars reflect the SD.

CD28 stimulation enhances IL-8 production by myeloma cells.

Jurkat T cells, RPMI 8226, SK-MM-1, or H929 human myeloma cells were stimulated with PMA, 25 ng/mL for Jurkat, SK-MM-1, and H929, 1 ng/mL for RPMI 8226, 1 μM ionomycin, 1 μg/mL anti-CD28, and/or 1 μg/mL isotype-matched control antibody MOPC195 as indicated. The cells were used at a concentration of 1 × 106/mL. After 18 hours, the supernatants were tested for IL-8 by ELISA, using the matched antibody pair and reagents from Pierce-Endogen as per the manufacturer's instructions. Within each experiment, the stimulations were performed in triplicate. The results shown are the average of 3 independent experiments. Error bars reflect the SD.

Close Modal

or Create an Account

Close Modal
Close Modal